2020 STO Fellows’ Forum
Agenda (PDF)
2020 Presentations
Cancer Drug Development: Views from Academia
Bernardo H.L. Goulart, MD, MS
University of Washington
Seattle Cancer Care Alliance, Seattle, Washington, USA
University of Washington
Seattle Cancer Care Alliance, Seattle, Washington, USA
Cancer Drug Development: Views from Industry
Peter Hammerman, MD
Novartis Institutes for Biomedical Research
Cambridge, Massachusetts, USA
Novartis Institutes for Biomedical Research
Cambridge, Massachusetts, USA
The Cost and Value of Cancer Medicine
Thomas Roberts, MD
Farallon Capital Management
San Francisco, California, USA
Farallon Capital Management
San Francisco, California, USA
Oncology Drug Development: A Regulatory Perspective
Tatiana Prowell, MD
US Food and Drug Administration,
Silver Spring, Maryland, USA
US Food and Drug Administration,
Silver Spring, Maryland, USA
Overcoming Barriers in Career Development and Progression
Ross Levine, MD
Memorial Sloan Kettering Cancer Center,
New York, New York, USA
Memorial Sloan Kettering Cancer Center,
New York, New York, USA
Systemic/Toxic Effects
Chloé Villani, PhD
Harvard Medical School, Massachusetts General Hospital
Charlestown, Massachusetts, USA
Harvard Medical School, Massachusetts General Hospital
Charlestown, Massachusetts, USA
Science at the Interface between the Lab and the Clinic
Ryan Corcoran, MD, PhD
Massachusetts General Hospital Cancer Center,
Boston, Massachusetts, USA
Massachusetts General Hospital Cancer Center,
Boston, Massachusetts, USA
CAR T Cells and Toxicities/Efficacy
Bianca Santomasso, MD
Memorial Sloan Kettering Cancer Center
New York, New York, USA
Memorial Sloan Kettering Cancer Center
New York, New York, USA
Phase I Clinical Trials: Hypothesis Testing
Keith Flaherty, MD
Massachusetts General Hospital Cancer Center,
Boston, Massachusetts, USA
Massachusetts General Hospital Cancer Center,
Boston, Massachusetts, USA
Issues in Design of Translational Research Trials
Susan Hilsenbeck, PhD
Baylor College of Medicine,
Houston, Texas, USA
Baylor College of Medicine,
Houston, Texas, USA
IRB Issues and Translational Research PI Responsibilities and Conflict of Interest
Stacey Berg, MD
Texas Children’s Cancer Center, Texas Children’s Hospital,
Baylor College of Medicine, Houston, Texas, USA
Texas Children’s Cancer Center, Texas Children’s Hospital,
Baylor College of Medicine, Houston, Texas, USA
Quantitative and Systems Pharmacology Approach to Personalizing Therapy
Michael Maitland, MD
Schar Cancer Institute, Inova Health System,
Annandale, Virginia, USA
Schar Cancer Institute, Inova Health System,
Annandale, Virginia, USA
Immune Checkpoint Inhibition in Advanced Cancer
Michael Postow, MD
Memorial Sloan Kettering Cancer Center
New York, New York. USA
Memorial Sloan Kettering Cancer Center
New York, New York. USA
Therapeutic Resistance Including Serial Biopsy, Rapid Autopsy and Blood-based Biomarkers Platforms
Dejan Juric, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, USA
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, USA
STO gratefully acknowledges support from:
 |
 |
 |
